Shelter Pharma Limited has announced the conversion of 7,35,000 convertible equity warrants into equity shares, as approved by its Board of Directors. This move has resulted in an increase in the company's paid-up share capital and has brought in additional funds from non-promoter investors.

Key Details of the Conversion

The conversion of warrants to equity shares was executed at a price of Rs. 31.75 per share, raising a total of Rs. 2.33 crore for the company. Here are the essential details of the transaction:

Impact on Share Capital

As a result of this conversion, Shelter Pharma's paid-up equity share capital has seen a notable increase:

Investor Details

The conversion was carried out by three non-promoter investors. The breakdown of their investments is as follows:

Regulatory Compliance and Next Steps

The company has stated that the newly allotted equity shares will rank pari-passu with the existing equity shares in all respects. Shelter Pharma plans to apply for listing and trading approval of these newly issued shares on the stock exchange in due course.

This warrant conversion is part of a larger allotment of 88,08,000 Convertible Equity Warrants that was approved earlier. The company had received in-principle approval from BSE Limited for this preferential allotment on July 22.

Shelter Pharma's management has confirmed that all necessary disclosures have been made in compliance with SEBI regulations, and the details of the transaction have been made available on the company's website.

Investors and market participants are advised to monitor further announcements from the company regarding the listing of these new shares and any potential impact on the stock's trading dynamics.

Shelter Pharma Limited has confirmed that there has been no deviation or variation in the utilization of proceeds from its recent preferential issue of warrants convertible into equity shares. The company raised Rs. 9.30 crore through the allotment of 88,08,000 warrants at Rs. 42.25 each on August 6, 2025.

Warrant Issuance Details

The company received 25% of the subscription amount, totaling Rs. 9,30,34,500, for the warrants issued. The funds were allocated as follows:

These allocations are in line with the objects approved in the Extraordinary General Meeting held on July 23, 2025.

Utilization of Funds

According to the Statement of Deviation and Variation provided by the company's auditors, the entire amount of Rs. 930.35 lakhs received has been utilized for working capital requirements, as per the disclosed objectives.

Future Payments

Shelter Pharma noted that the remaining 75% of the warrant subscription amount will be received within 18 months, in accordance with ICDR (Issue of Capital and Disclosure Requirements) regulations.

Financial Performance

For the half-year ended September 30, 2025, Shelter Pharma reported the following financial results:

The company's performance shows an improvement compared to the previous periods, with increased revenue and profitability.

Balance Sheet Highlights

As of September 30, 2025, Shelter Pharma's balance sheet reflects the following:

The company's financial position appears to have strengthened, with an increase in reserves and surplus, and the addition of funds from the warrant issue.

Shelter Pharma Limited continues to focus on its core business of manufacturing pharmaceuticals, with no changes reported in its segment operations. The company's management and auditors have ensured compliance with regulatory requirements, including the timely filing of financial results and utilization reports.